A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China

Vaccine

Volumn 26, Issue 35, 2008, Pages 4608-4616

  Zhuang, Gui Hua ^a   Pan, Xin Juan ^a   Wang, Xue Liang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Cost effectiveness; Hepatitis A; Vaccination

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; INACTIVATED VACCINE;

ARTICLE; CHINA; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SCREENING; FEMALE; HEALTH CARE; HEPATITIS A; HUMAN; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SOCIOECONOMICS; VACCINATION;

CHINA; COST-BENEFIT ANALYSIS; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION PROGRAMS; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; SEROEPIDEMIOLOGIC STUDIES; TREATMENT OUTCOME;

EID: 48449106297     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.086     Document Type: Article

References (43)

1. World Health Organization. Hepatitis A vaccines: WHO position paper. Weekly Epidemiological Record 2000;75(5):38-42. Available at URL: http://www.who.int/wer/pdf/2000/wer7505.pdf.
2. Lednar W.M., Lemon S.M., Kirkpatrick J.W., Redfield R.R., Fields M.L., and Kelley P.W. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 122 2 (1985) 226-233
3. Lemon S.M. Type A viral hepatitis: epidemiology, diagnosis, and prevention. Clin Chem 43 8(B) (1997) 1494-1499
4. Almasio P.L., and Amoroso P. HAV infection in chronic liver disease: a rationale for vaccination. Vaccine 21 19-20 (2003) 2238-2241
5. Jacobsen K.H., and Koopman J.S. The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. Int J Epidemiol 34 3 (2005) 600-609
6. Barzaga B.N. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine 18 Suppl. 1 (2000) S61-S64
7. Valenzuela M.T., Jacobs R.J., Arteaga O., Navarrete M.S., Meyerhoff A.S., and Innis B.L. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine 23 32 (2005) 4110-4119
8. Dai Z.C., and Qi G.M. Viral hepatitis in China: seroepidemiological survey in Chinese population, 1992-1995 (part one) (1999), Scientific and Technical Documents Publishing House, Beijing
9. Xu Z.Y., Li Z.H., Wang J.X., Xiao Z.P., and Dong D.X. Ecology and prevention of a shellfish-associated hepatitis A epidemic in Shanghai, China. Vaccine 10 Suppl. 1 (1992) S67-S68
10. Zhuang F.C., Qian W., Mao Z.A., Gong Y.P., Jiang Q., Jiang L.M., et al. Persistent efficacy of live attenuated hepatitis A vaccine (H2-strain) after a mass vaccination program. Chin Med J 118 22 (2005) 1851-1856
11. Wang X.Y., Xu Z.Y., Ma J.C., von Seidlein L., Zhang Y., Hao Z.Y., et al. Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up. Vaccine 25 3 (2007) 446-449
12. Ren A., Feng F., Ma J., Xu Y., and Liu C. Immunogenicity and safety of a new inactivated hepatitis A vaccine in young adults: a comparative study. Chin Med J 115 10 (2002) 1483-1485
13. Yin W.D. The Healive™ inactivated domestic hepatitis A vaccine: production and application. Chin J Vaccines Immun 10 3 (2004) 174-177
14. Liu C.B., Ren Y.H., Zhang Y.C., Wu W.T., Li S.P., Kang W.X., et al. The study on immunogenicity, safety and vaccination schedule of a new inactivated hepatitis A vaccine in Chinese children. Chin J Vaccines Immun 8 1 (2002) 1-3
15. Van Herck K., Van Damme P., Lievens M., and Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol 72 2 (2004) 194-196
16. Van Damme P., Banatvala J., Fay O., Iwarson S., McMahon B., Van Herck K., et al. Hepatitis A booster vaccination: is there a need?. Lancet 362 9389 (2003) 1065-1071
17. Rein D.B., Hicks K.A., Wirth K.E., Billah K., Finelli L., Fiore A.E., et al. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics 119 1 (2007) e12-e21
18. Lopez E., Debbag R., Coudeville L., Baron-Papillon F., and Armoni J. The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis. J Gastroenterol 42 2 (2007) 152-160
19. Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults. Hepatology 37 1 (2003) 44-51
20. Demicheli V., Carniglia E., and Fucci S. The use of hepatitis A vaccination in Italy: an economic evaluation. Vaccine 21 19-20 (2003) 2250-2257
21. Ginsberg G.M., Slater P.E., and Shouval D. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J Hepatol 34 1 (2001) 92-99
22. Das A. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. Hepatology 29 2 (1999) 548-552
23. Averhoff F., Shapiro C.N., Bell B.P., Hyams I., Burd L., Deladisma A., et al. Control of hepatitis A through routine vaccination of children. JAMA 286 23 (2001) 2968-2973
24. Dominguez A., Salleras L., Carmona G., and Batalla J. Effectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine 21 7-8 (2003) 698-701
25. Bialek S.R., Thoroughman D.A., Hu D., Simard E.P., Chattin J., Cheek J., et al. Hepatitis A incidence and hepatitis A vaccination among American Indians and Alaska Natives, 1990-2001. Am J Public Health 94 6 (2004) 996-1001
26. The Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 55 RR-7 (2006) 1-23
27. Jacobs R.J., Greenberg D.P., Koff R.S., Saab S., and Meyerhoff A.S. Regional variation in the cost effectiveness of childhood hepatitis A immunization. Pediatr Infect Dis J 22 10 (2003) 904-914
28. Grenfell B.T., and Anderson R.M. The estimation of age-related rates of infection from case notifications and serological data. J Hyg (Lond) 95 2 (1985) 419-436
29. Griffiths D.A. A catalytic model of infection for measles. Appl Stat 23 3 (1974) 330-339
30. Armstrong G.L., and Bell B.P. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 109 5 (2002) 839-845
31. Ellis A., Rüttimann R.W., Jacobs R.J., Meyerhoff A.S., and Innis B.L. Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted. Pan Am J Public Health 21 6 (2007) 345-356
32. Center for Health Statistics and Information of Ministry of Health. An analysis report of national health services survey in 2003 (2004), Chinese Academy of Medical Science & Peking Union Medical College Press, Beijing
33. Jacobs R.J., Margolis H.S., and Coleman P.J. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch Pediatr Adol Med 154 8 (2000) 763-770
34. The Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 48 RR-12 (1999) 1-37
35. Berge J.J., Drennan D.P., Jacobs R.J., Jakins A., Meyerhoff A.S., Stubblefield W., et al. The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 31 2 (2000) 469-473
36. Garattini L., Tediosi F., Ghislandi S., Orzella L., and Rossi C. How do Italian pharmacoeconomists evaluate indirect costs?. Value Health 3 4 (2000) 270-276
37. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., and Russell L.B. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276 15 (1996) 1253-1258
38. Jacobs R.J., Moleski R.J., and Meyerhoff A.S. Valuation of symptomatic hepatitis a in adults: estimates based on time trade-off and willingness-to-pay measurement. Pharmacoeconomics 20 11 (2002) 739-747
39. Zhuang G.H., and XU H.W. The use of decision making analysis for evaluating hepatitis B inoculation strategy. Chin J Prevent Med 27 2 (1993) 69-73
40. Ikematsu H., Kashiwagi S., Hayashi J., Nomura H., Kajiyama W., Tani S., et al. A seroepidemiologic study of hepatitis A virus infections: statistical analysis of two independent cross-sectional surveys in Okinawa, Japan. Am J Epidemiol 126 1 (1987) 50-54
41. Amela C., Pachón I., Bueno R., de Miguel C., and Martinez-Navarro F. Trends in hepatitis A virus infection with reference to the process of urbanization in the greater Madrid area (Spain). Eur J Epidemiol 11 5 (1995) 569-573
42. Saab S., Martin P., and Yee Jr. H.F. A simple cost-decision analysis model comparing two strategies for hepatitis A vaccination. Am J Med 109 3 (2000) 241-244
43. Rein D.B., Fiore A.E., and Bell B.P. What's next for the hepatitis A vaccine?. Lancet 367 9510 (2006) 546-548